Gapping up
In reaction to earnings/guidance:
- BKE +12.8%, FL +5.7%, KEYS +3.9%, DE +2.6%, ROST +0.6%, MMYT +0.6%
Other news:
- SCPH +9.5% (enters into a supply agreement with WST)
- MOBL +7.2% (co will explore potential sale, according to Bloomberg)
- BNTX +6.2% (BioNTech and Pfizer share early results on lead mRNA vaccine candidate BNT162b2 against COVID-19)
- XSPA +3.7% (opens XpresCheck COVID-19 testing facility)
- XERS +3.5% (names new COO)
- TLSA +3.4% (receives patent for use of milciclib in combination with tyrosine kinase inhibitors)
- PSTX +3.2% (provides operational update)
- SRNE +2.5% (to acquire SmartPharm)
- MIK +1.2% (names new CFO)
- CYRX +1.1% (to acquire CRYOPDP, a global provider of temperature-controlled logistics solutions to the clinical research, pharmaceutical and cell and gene therapy markets)
- PFE +1% (BioNTech and Pfizer share early results on lead mRNA vaccine candidate BNT162b2 against COVID-19)
Analyst comments:
- CXO +2.3% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- EL +1.7% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- PANW +0.9% (initiated with a Buy at Loop Capital)
- SPLK +0.9% (initiated with a Buy at Loop Capital)
- WSM +0.7% (upgraded to Buy from Accumulate at Gordon Haskett)